Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

The Mescal family’s lives have changed tenfold in recent years, with two of the children forging careers in the spotlight and even mum Dearbhla becoming a well-known face. Dearbhla, who was diagnosed ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab ...

At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is ...

My blood work showed that I was slightly low in vitamin D, so my doctor recommended that I take a supplement. My pharmacist ...

The rapid increase in demand for artificial intelligence as the technology is adopted and implemented by public- and private-sector businesses is driving the surge in data center construction ...

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...